SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 40-F/A - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)]: [Amend]
SEC Accession No. 0001493152-21-028949
Filing Date
2021-11-16
Accepted
2021-11-16 16:05:49
Documents
87
Period of Report
2021-07-31

Document Format Files

Seq Description Document Type Size
1 form40-fa.htm   iXBRL 40-F/A 53105
2 ex99-1.htm   iXBRL EX-99.1 1308925
3 ex99-4.htm EX-99.4 18940
4 ex99-5.htm EX-99.5 19479
5 ex99-6.htm EX-99.6 7495
6 ex99-7.htm EX-99.7 7426
7 ex99-8.htm EX-99.8 4723
8 ex99-1_001.jpg GRAPHIC 16715
9 ex99-1_002.jpg GRAPHIC 1823
10 ex99-1_003.jpg GRAPHIC 2516
  Complete submission text file 0001493152-21-028949.txt   8310976

Data Files

Seq Description Document Type Size
11 XBRL SCHEMA FILE bct-20210731.xsd EX-101.SCH 89011
12 XBRL CALCULATION FILE bct-20210731_cal.xml EX-101.CAL 67887
13 XBRL DEFINITION FILE bct-20210731_def.xml EX-101.DEF 281342
14 XBRL LABEL FILE bct-20210731_lab.xml EX-101.LAB 506836
15 XBRL PRESENTATION FILE bct-20210731_pre.xml EX-101.PRE 386296
16 EXTRACTED XBRL INSTANCE DOCUMENT form40-fa_htm.xml XML 1684212
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 40-F/A | Act: 34 | File No.: 001-40101 | Film No.: 211416075
SIC: 2834 Pharmaceutical Preparations